US FDA’s Biosimilars Group Will Conduct Some Supplement Reviews, Become ‘Like Another Discipline’
Office of Therapeutic Biologics and Biosimilars Director Sarah Yim says in an interview with the Pink Sheet that more staff are being added to deal with labeling supplements.
